Invitrogen scientists will support research programs at the Pharmacogenomics Centre to improve the efficiency and speed with which researchers can identify single nucleotide polymorphisms (SNPs), differences in single base pairs that typically occur in more than one percent of the population.
Researchers at the Pharmacogenomics Centre are seeking to identify new SNPs within approximately 200 specific ADME/Tox-related genes that effect how a drug is metabolized by an individual.
To identify these SNPs, researchers must analyze the ADME/Tox genes of a population of people through targeted medical resequencing. The collaboration focuses on ways to accelerate this process, thereby speeding the research.
Rob Bennett, vice president of advanced sequencing applications at Invitrogen, said: “This collaboration offers Invitrogen the opportunity to work closely with thought leaders in the field of pharmacogenomics and to better understand this emerging area of research. We are excited about combining our technologies and enzymology know-how with the Pharmacogenomics Centre’s knowledge of ADME/Tox genes.”